Merck KGaA (MRK) Given a €100.00 Price Target at Warburg Research
Warburg Research set a €100.00 ($116.28) price objective on Merck KGaA (FRA:MRK) in a research report sent to investors on Tuesday. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other research firms have also commented on MRK. Barclays set a €70.00 ($81.40) price target on Merck KGaA and gave the stock a sell rating in a research report on Friday, August 24th. Sanford C. Bernstein set a €105.00 ($122.09) price target on Merck KGaA and gave the stock a buy rating in a research report on Tuesday, July 3rd. Berenberg Bank set a €102.00 ($118.60) price target on Merck KGaA and gave the stock a buy rating in a research report on Thursday, August 30th. Goldman Sachs Group set a €92.00 ($106.98) price target on Merck KGaA and gave the stock a neutral rating in a research report on Wednesday, September 12th. Finally, Societe Generale set a €92.00 ($106.98) price target on Merck KGaA and gave the stock a neutral rating in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. Merck KGaA presently has a consensus rating of Hold and an average price target of €98.76 ($114.84).
Shares of FRA MRK opened at €93.72 ($108.98) on Tuesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: What Does Beta Mean In Stock Selection
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.